Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of single-dose XMVA09 in wet age-related macular degeneration
CTR20241282Phase 2Active
- Sponsor
- Starrygene Therapeutics
- Start
- Jun 2024
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, AAV Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of XMVA09 in exudative macular degeneration, sponsored by Starrygene Therapeutics. Started Jun 2024; status: active.
02
Drugs
XMVA09
03
Conditions
exudative macular degeneration
Beyond the preview
Go deeper on CTR20241282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20241282.